These include a phase III trial studying vorasidenib versus a placebo in patients with residual or recurrent IDH mutant gliomas grades 2 or 3 (NCT04164901) and a study of DS-1001 in patients with chemotherapy- and radiotherapy-naïve IDH1-mutated WHO grade 2 gliomas (NCT04458272). Here, IDH2 is linked to central nervous system cancer.